Tower Research Capital (TRC)’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-7,135
Closed -$2.84K 6414
2023
Q3
$2.84K Sell
7,135
-15
-0.2% -$7 ﹤0.01% 5095
2023
Q2
$4.93K Buy
7,150
+6,664
+1,371% +$42.9K ﹤0.01% 4885
2023
Q1
$4K Sell
486
-5,386
-92% -$18.8K ﹤0.01% 5159
2022
Q4
$5K Sell
5,872
-1,689
-22% -$1.73K ﹤0.01% 4961
2022
Q3
$8K Sell
7,561
-3,064
-29% -$4.01K ﹤0.01% 4854
2022
Q2
$13K Buy
10,625
+9,049
+574% +$12.1K ﹤0.01% 4263
2022
Q1
$4K Buy
1,576
+878
+126% +$2.09K ﹤0.01% 5335
2021
Q4
$2K Buy
+698
New +$2.32K ﹤0.01% 5765
2021
Q2
Sell
-2,131
Closed -$11K 6338
2021
Q1
$11K Buy
2,131
+689
+48% +$4.8K ﹤0.01% 4353
2020
Q4
$10K Sell
1,442
-2,110
-59% -$17.3K ﹤0.01% 4360
2020
Q3
$36K Buy
3,552
+3,381
+1,977% +$39.8K ﹤0.01% 3671
2020
Q2
$2K Buy
+171
New +$2.39K ﹤0.01% 4574
2017
Q4
Sell
-7
Closed 4301
2017
Q3
$0 Buy
+7
New +$130 ﹤0.01% 4325
2016
Q4
Sell
-47
Closed -$1K 4701
2016
Q3
$1K Sell
47
-2
-4% -$48 ﹤0.01% 3444
2016
Q2
$1K Hold
49
﹤0.01% 4282
2016
Q1
$2K Buy
+49
New +$1.82K ﹤0.01% 3517
2015
Q4
Sell
-13
Closed -$1K 5350
2015
Q3
$1K Sell
13
-10
-43% -$770 ﹤0.01% 3756
2015
Q2
$3K Buy
23
+1
+5% +$136 ﹤0.01% 3616
2015
Q1
$3K Buy
+22
New +$3.42K ﹤0.01% 3641

Other funds holding BLPH

Tower Research Capital (TRC)'s BLPH Position: Q4 2023 in Review

Tower Research Capital (TRC) sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q4 2023, closing a stake of 7,135 shares — an estimated $2.84K sold.

Tower Research Capital (TRC) first reported a position in BLPH in Q1 2015 and held it in 19 quarters. The position peaked at $36K in Q3 2020. 2 funds tracked by Wall St. Rank hold BLPH as of Q4 2023.

  • Tower Research Capital (TRC) reported no remaining Bellerophon Therapeutics, Inc. position as of Q4 2023 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 7,135 Bellerophon Therapeutics, Inc. shares in Q4 2023, an estimated $2.84K.
  • Tower Research Capital (TRC) first reported a position in Bellerophon Therapeutics, Inc. in Q1 2015 and held it in 19 quarters.
  • Tower Research Capital (TRC)'s Bellerophon Therapeutics, Inc. position peaked at $36K in Q3 2020.
  • 2 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q4 2023.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2023, filed 13 Feb 2024.